Needham Reiterates Buy on Harmony Biosciences, Maintains $52 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintains a $52 price target.
August 06, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Harmony Biosciences and maintains a $52 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $52 price target by a reputable analyst suggests a positive outlook for Harmony Biosciences. This could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100